MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Status:
Recruiting
Trial end date:
2021-12-20
Target enrollment:
Participant gender:
Summary
Twelve patients with relapsed malignant pleural mesothelioma will be treated with
intratumoral injections of MTG201, a replication incompetent adenovirus, modified by the
insertion of the reduced expression in immortalized cells (REIC)/Dikkopf (Dkk)-3 gene, on
Days 1, 8, 22, and 50. Patients will also receive every 4 weekly intravenous infusions of
nivolumab, 480 mg, starting on Day 2. Safety and anti-tumor activity will be monitored at
regular intervals throughout the study.